NAMSA was the first independent company in the world to focus solely on testing medical device materials for safety. NAMSA’s suite of services are designed to lower development costs and accelerate regulatory approval and commercialization globally for medical device and in-vitro diagnotics (IVD) technologies. NAMSA offers expert medical device testing, regulatory, reimbursement and quality consulting services, and clinical research support to aid clients at every stage in the medical device development continuum.
NAMSA is the third acquisition of ArchiMed’s recently closed 1 billion euro ($1.2 billion) MED Platform I buy-and-build fund. MED Platform I partners with growth companies in the European and North American mid-cap healthcare sectors, buying majority stakes for 50 million euros to 500 million euros in association with existing owners and managers. MED Platform I provides its companies with the strategic, tactical and financial resources they need to broaden product lines, expand into new regions and consolidate sectors.
“Investment from a strategic partner is essential for NAMSA’s next era of growth,” said Gorski. “ArchiMed didn’t just bring financing to the table, they also have a sophisticated understanding of how to achieve success in this industry, particularly through a buy-and-build strategy. ArchiMed’s global network of relationships in the medical device business will broaden our client base, while the capital access, industry experience and deal acumen we gain will accelerate our international growth, both organically and via acquisition.”
“There is a fantastic cultural fit between ArchiMed and NAMSA and we share the same vision for the future,” said ArchiMed Chairman Denis Ribon. “NAMSA is the global leader in a fragmented, fast growing field, bursting with technological innovation. The latter is particularly evident in the area of wearable devices that are increasingly being adapted to diagnose, monitor and manage life threatening medical conditions.”
“ArchiMed and NAMSA see huge potential for growth in the medical device services market across the entire spectrum of testing, clinical trials and consulting,” added André-Michel Ballester, managing partner of the MED Platform I fund.